Value of Treatment by Comprehensive Stroke Services for the reduction of critical gaps in acute stroke care in Europe.

Abstract

Stroke is the second leading cause of death and dependency in Europe and costs the EU >€30 billion, yet significant gaps in the patient pathway remain and the cost-effectiveness of comprehensive stroke care to meet these needs is unknown. The European Brain Council Value of Treatment Initiative combined patient representatives, stroke experts, neurological societies and literature review to identify unmet needs in the patient pathway according to Rotterdam methodology. Cost-effectiveness of Comprehensive Stroke Services was determined by a Markov model, using UK cost data as an exemplar and efficacy data for prevention of death and dependency from published systematic reviews and trials, expressing effectiveness as Quality Adjusted Life-Years (QALYs). Model outcomes included total costs, total QALYs, incremental costs, incremental QALYs and the incremental cost-effectiveness ratio (ICER). Key unmet needs in the stroke patient pathway included inadequate treatment of atrial fibrillation, access to neurorehabilitation and implementation of Comprehensive Stroke Services. In the Markov model, full implementation of Comprehensive Stroke Services was associated with a 9.8% absolute reduction in risk of death of dependency, at an intervention cost of £9,566 versus £6,640 for standard care, and long-term care costs of £35,169 per 5.1251 QALYS vs £32,347.40 per 4.5853 QALYs, resulting in an ICER of £5,227.89. Results were robust in one-way and probabilistic sensitivity analyses. Implementation of Comprehensive Stroke Services is a cost-effective approach to meet unmet needs in the stroke patient pathway, to improve acute stroke care and support better treatment of atrial fibrillation and access to neurorehabilitation.